Ilan Goldenberg

2 months ago | contrarian.substack.com | Ilan Goldenberg

In the barrage of executive edicts and harmful week one actions by the Trump Administration, one of the most damaging has been the approach to “immediately pause new obligations and disbursements” of funding for 90 days for all foreign aid. This order is already harming U.S. national interests and will likely result in thousands losing their jobs. People could die. It is a brutally inefficient way to run a government. President Trump was always clear about his priorities.

Jan 15, 2025 | contrarian.substack.com | Ilan Goldenberg

This is not the first column I expected to write for The Contrarian. I presumed it would be my personal story and how I’ve wrestled with issues associated with Israel, the Israeli-Palestinian conflict, and the Middle East. Instead, I am thrilled that after fifteen months of agony in Israel and in Gaza, my first piece is about an agreement on a ceasefire and a hostage deal. The agreement will be broken into three phases.

Apr 12, 2024 | onlinelibrary.wiley.com | Hassan Abbas |Arwa Younis |Ilan Goldenberg |Scott McNitt

DATA AVAILABILITY STATEMENT The data that support the findings of this study are available from the corresponding author upon reasonable request.

Oct 1, 2023 | jacc.org | Alexander Diamond |Ilan Goldenberg |Arwa Younis |Ido Goldenberg

References1. "Beta-blockers for the prevention of sudden cardiac death in heart failure patients: a meta-analysis of randomized controlled trials". BMC Cardiovasc Disord . 2013;13:1: 52. https://doi.org/10.1186/1471-2261-13-52. 2. "Beta-blocker treatment in heart failure". Fundam Clin Pharmacol . 2001;15:2: 95-109. 3. "The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial". Lancet . 1999;353:9146: 9-13. 4.

Aug 28, 2023 | ecrjournal.com | Frederick J. Raal |Ilan Goldenberg

ESC 23 — Prof Frederick Raal (University of the Witwatersrand, Johannesburg, SA) outlines the late-breaking results from the LIBerte-HeFH study (NCT04797104). The phase III LIBerte-HeFH study (LIB Therapeutics LLC) aimed to assess the effectiveness of PCSK9-inhibitor Ierodalcibep (LIB003) in reducing low-density lipoprotein cholesterol (LDL-C) in 300mg doses administered subcutaneously in patients with heterozygous familial hypercholesterolemia as compared to placebo.